Drug Profile
Tolcapone - Corino Therapeutics/SOM Biotech
Alternative Names: CRX-1008; SOM 0226Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator SOM Biotech
- Developer Corino Therapeutics; SOM Biotech; Vall d-Hebron Research Institute
- Class Antiparkinsonians; Benzophenones; Nitrophenols; Small molecules
- Mechanism of Action Catechol O-methyltransferase inhibitors; Prealbumin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Amyloid polyneuropathy
Highest Development Phases
- Phase II Familial amyloid neuropathy
- No development reported Transthyretin-related hereditary amyloidosis
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-0 development in Transthyretin-related-hereditary-amyloidosis in USA (PO)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Familial-amyloid-neuropathy(In volunteers) in United Kingdom (PO, Tablet)
- 15 Sep 2020 Interim efficacy and adverse events data from a phase 0 trial in transthyretin related hereditary amyloidosis released by Corino Therapeutics